Safety and efficacy of calcium folinate in psoriasis: an observation study “

An association between psoriasis and cardio-metabolic conditions such as cardiovascular disease, diabetes, obesity and metabolic syndrome(MetS) has been reported; both posiasis and MetS have strong inflammatory components and their co-occurrence may be linked to this shared attribute. In clinical practice there are many psoriatic patients simultaneously affected by hypertension, diabetes, dyslipidemia, obesity. These patients could be marked as “complicated” patients. With the aim to find an alternative treatment for these patients, without increasing their cardiovascular risk, we revalued the physiological role of calcium and folic acid. To assess the efficacy and tolerability of a new drug, folinate calcium, to treat psoriasis, a total of 58 patients affected by active psoriasis were enrolled in a variable period study. These patients had clinically stable, plaque psoriasis involving ? 6% body surface area. Thirty of these patients were treated with folinate calcium therapy, 15 mg orally once daily, for a variable period based on each patient’s clinical response. The comparison was made with 28 psoriatic patients treated with conventional systemic therapies( cyclosporine, acitretin, etanercept, efalizumab, infliximab, adalimumab). A clinical improvement was observed in both group, but in the first one we did not observe any side effects, whereas some important side effects was observed in the second. These preliminary results support the effectiveness and tolerability of folinate calcium treatment in psoriasis.